希美宁对2型糖尿病高脂血症模型大鼠血脂、血流变及血清Leptin的影响
|
摘要
目的:研究希美宁对2型糖尿病(diabetes mellitus,DM)合并高脂血症(hyperlipidemia,HLP)大鼠的空腹血糖(fasting blood glucose,FBG)、血清胰岛素(insulin,INS)、糖化血红蛋白(glyxosylated hemoglobi,HbAIC)、血脂、血流变及血清瘦素(leptin)的影响,并探讨其作用机制。
方法:将80只SD雄性大鼠随机分为两组,即空白组和糖尿病组。空白组以普通饲料喂养,糖尿病组以高糖高脂饲料喂养。8周后,糖尿病组大鼠一次性腹腔注射小剂量链脲佐菌素(streptozotozin,STZ),损坏部分胰腺,诱发高血糖。1周后测血糖,以空腹血糖＞16.7mmol/L的大鼠为成功模型纳入实验。将纳入实验的糖尿病高脂血症大鼠随机分为糖尿病模型组、希美宁组、血脂康组。希美宁组和血脂康组按体重不同以成人剂量的0.018倍相应灌胃;空白组和模型组以等体积生理盐水给大鼠灌胃。14周末给药结束后,隔夜空腹摘眼球取血,收集血液,分装不同试管,测定血糖、血流变的水平,分离血清,以测定糖化血红蛋白、胰岛素、血脂及Leptin的水平。
结果:①采用高糖高脂饮食诱导+STZ综合造模法的模型组大鼠其血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin水平明显高于空白组,有统计学意义;②血脂康组治疗后的大鼠,其血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin水平较模型组显著降低,有统计学意义;③希美宁组其血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin水平低于血脂康组,有统计学意义。
结论:采用高糖高脂饮食诱导+STZ综合造模法成功复制糖尿病合并高脂血症大鼠的模型;希美宁对糖尿病合并高脂血症大鼠的血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin有显著治疗作用,其作用机制之一可能是通过抑制Leptin过度表达实现的。
Objective.To study the effects of Ximeining on blood lipid、hemorrheology and Leptin in serum of 2DM mice with hyperlipoidemia,and investigate its mechanism.
Methods:80 male rats were randomly divided into two groups,the blank group and diabetes group.To the control group fed normal diet,diabetes group high sugar and high fat diet.After eight weeks,the diabetes group was injected with low-dose streptozotocin(STZ),damaged part of the pancreas,induced by high blood sugar.One week later measure blood glucose,fasting plasma glucose(FBG)>16.7mmol/L,which were choosed into the model for successful experiments.Experimental diabetes will be divided into the model of diabetic rats,the XIMEINING group,and the XUEZHIKANG group.With saline gavage to blank and model group mice,the XIMEINING group and the XUEZHIKANG group treatment by different weight to adult dose of 0.018 times the corresponding administration.After 14 weekends administration,kill the animals by picking the overnight fasting blood eyeball,collecting the blood with different sub-tube,separating the serum,to determinate the level of glucose, glycated hemoglobin,serum insulin,blood lipids,hemorrheolog and Leptin.
Results:With high sugar and high fat diet + STZ integrated model of the mice model of their blood sugar,blood lipid,hemorrheolog and Leptin.Levels were significantly higher than the control group.With the ximeining group their blood sugar,blood lipid,hemorrheolog and TNF-αlevel compered with the model were significantly lower,Blood sugar and Leptin levels of XIMEINING group were lower than xuezhikang treatment group.It was statistically significant,blood lipid levels of XIMEINING group decreased compared with XUEZHIKANG group.It was statistically significant.
Conclusion:High sugar and high fat diet + STZ integrated model of successful replication of diabetic hyperlipidemia in the modeI,XIMEINING lipid metabolism of diabetic mice disorder of the blood sugar,blood lipid, hemorrheolog and Leptin treatment of a significant role.It's role is imposible one of the mechanisms by inhibiting Leptin to achieve the over-expression.
方法:将80只SD雄性大鼠随机分为两组,即空白组和糖尿病组。空白组以普通饲料喂养,糖尿病组以高糖高脂饲料喂养。8周后,糖尿病组大鼠一次性腹腔注射小剂量链脲佐菌素(streptozotozin,STZ),损坏部分胰腺,诱发高血糖。1周后测血糖,以空腹血糖＞16.7mmol/L的大鼠为成功模型纳入实验。将纳入实验的糖尿病高脂血症大鼠随机分为糖尿病模型组、希美宁组、血脂康组。希美宁组和血脂康组按体重不同以成人剂量的0.018倍相应灌胃;空白组和模型组以等体积生理盐水给大鼠灌胃。14周末给药结束后,隔夜空腹摘眼球取血,收集血液,分装不同试管,测定血糖、血流变的水平,分离血清,以测定糖化血红蛋白、胰岛素、血脂及Leptin的水平。
结果:①采用高糖高脂饮食诱导+STZ综合造模法的模型组大鼠其血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin水平明显高于空白组,有统计学意义;②血脂康组治疗后的大鼠,其血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin水平较模型组显著降低,有统计学意义;③希美宁组其血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin水平低于血脂康组,有统计学意义。
结论:采用高糖高脂饮食诱导+STZ综合造模法成功复制糖尿病合并高脂血症大鼠的模型;希美宁对糖尿病合并高脂血症大鼠的血糖、血清胰岛素、糖化血红蛋白、血脂、血流变、Leptin有显著治疗作用,其作用机制之一可能是通过抑制Leptin过度表达实现的。
Objective.To study the effects of Ximeining on blood lipid、hemorrheology and Leptin in serum of 2DM mice with hyperlipoidemia,and investigate its mechanism.
Methods:80 male rats were randomly divided into two groups,the blank group and diabetes group.To the control group fed normal diet,diabetes group high sugar and high fat diet.After eight weeks,the diabetes group was injected with low-dose streptozotocin(STZ),damaged part of the pancreas,induced by high blood sugar.One week later measure blood glucose,fasting plasma glucose(FBG)>16.7mmol/L,which were choosed into the model for successful experiments.Experimental diabetes will be divided into the model of diabetic rats,the XIMEINING group,and the XUEZHIKANG group.With saline gavage to blank and model group mice,the XIMEINING group and the XUEZHIKANG group treatment by different weight to adult dose of 0.018 times the corresponding administration.After 14 weekends administration,kill the animals by picking the overnight fasting blood eyeball,collecting the blood with different sub-tube,separating the serum,to determinate the level of glucose, glycated hemoglobin,serum insulin,blood lipids,hemorrheolog and Leptin.
Results:With high sugar and high fat diet + STZ integrated model of the mice model of their blood sugar,blood lipid,hemorrheolog and Leptin.Levels were significantly higher than the control group.With the ximeining group their blood sugar,blood lipid,hemorrheolog and TNF-αlevel compered with the model were significantly lower,Blood sugar and Leptin levels of XIMEINING group were lower than xuezhikang treatment group.It was statistically significant,blood lipid levels of XIMEINING group decreased compared with XUEZHIKANG group.It was statistically significant.
Conclusion:High sugar and high fat diet + STZ integrated model of successful replication of diabetic hyperlipidemia in the modeI,XIMEINING lipid metabolism of diabetic mice disorder of the blood sugar,blood lipid, hemorrheolog and Leptin treatment of a significant role.It's role is imposible one of the mechanisms by inhibiting Leptin to achieve the over-expression.
引文
[1]李秀钧,邬云红.糖尿病是一种炎症性疾病.[J].中华内分泌代谢杂志,2003,19:251-253.
[2]Barzilay JI,AbrahamL,Heckbert SR,et al.The relation of markers of Inflammation to the development of glueose disorders in the elderly:the Cardiovascular health study[J].Diabetes,2001,50:2384.
[3]Pradhan AD,Manson JE,Rifai N,etal.C-reaetive protein,inter leukine,and risk of developing type 2 diabetes mellitus[J].JAMA,2001,286:327.
[4]杨金奎,成金罗等 家族性2型糖尿病遗传方式及血糖血脂代谢的研究.[J].江苏临床医学杂志,2002,6(4):322-324.
[5]卢薇,汪晓云,杨正平等2型糖尿病患者餐后血糖、血脂与凝血及血小板活性关系[J].临床内科杂志,2002,19(6):472-473.
[6]张英新.益气健脾法与糖尿病.山东中医学院杂志,1995;(6):391.
[7]邢玖.从“脾”论治糖尿病-附30例疗效分析.中医药研究,1997;(5):18.
[8]郑庆瑞.健脾补肾活血化癖治疗性糖尿病.新中医,1996:28(4):58.
[9]杨坚毅.老年高脂血症的中医分型治疗.新中医,1996;28(8):6.
[10]靳瑞主编.针灸医籍选.人民卫生出版社,1990;113.
[11]《袖珍中医四部经典》.天津科学技术出版社,1992;90-91.
[12]张兆云.中医药防止高脂血症信息分析.中国中医药信息杂志,1994;(6):33.
[13]李中梓.《医宗必读》.三余堂详较本,卷9:16.
[14]张景岳.《景岳全书》.上海科学技术出版社,1980年:531.
[15]丁汀辨病与辨证相结合治疗高脂血症[J].天津药学,200315(1):34.
[16]倪青.脾胃肾虚生痰湿祛痰利湿重健脾.辽宁中医杂志,2001,28(4):195-196.
[17]丁宇炜,徐瑛,沈丕安.中医分型治疗高脂血症45例观察[J].内蒙古中医药,2003(4):1.
[18]卢秀鸾,曲竹秋,贾锡莲.降糖克脂胶囊治疗老年性糖尿病合并高血脂症68例观察.中草药,2000,31(5):368.
[19]崔衍富.血塞通结合辨证治疗高脂血症100例[J]辽宁中医杂志,1997,24(9):403.
[20]何锦花.高脂血症辨证施治[J]广西中医药,1995,18(1):23.
[21]高雷,林海平,王超.补肾通脉丸治疗糖尿病并发高脂血症368例[J].辽宁中医杂志,2003,30(8):616.
[22]王旭.益肾活血化浊法治疗老年糖尿病合并高脂血症的临床研究[A].第四届全国糖尿病(消渴病)学术研讨会论文集[C].济南:山东科学技术出版社,1997,71-72.
[23]汪何.吕雄.刘乡等.中西医结合治疗 2 型糖尿病合并高脂血症[J].广东医学,2002,23(2):201.
[24]沈志卫,于普林.血脂康治疗原发性高血脂的前瞻性研究.中华医学杂志,1996,76(2):156.
[25]肖超烈,姚志强,贺淑梅.血脂康与脂必妥对高胆固醇血症的调脂作用比较[J].广东医学,2000,21(51):349.
[26]孙炜.祛瘀化痰通络论治糖尿病高脂血症56例[J].中国医药学报,2003,18(8):508
[27]龚振岭,靳国春,康胜群.胰体康胶囊治疗2型糖尿病125例临床研究[J].河北中医,2002,24(2):83-86.
[28]周晓,张炜宁,曾庆明,等.清化消瘀方治疗2型糖尿病合并高脂血症36例总结[J]湖南中医杂志,2003,19(4):13.
[29]王红,申凤菊三参二根汤治疗2型糖尿病并高脂血症[J].山东医药工业,2003,22(4):58
[30]吴深涛,黄怀鹏,邬金玲等.肾消颗粒对早期糖尿病影响的研究.天津中医药,2004,21(6):473.
[31]郭宝荣,冯建华,杨文军.降糖活血调脂汤治疗糖尿病合并高脂血症52例[J].山东中医药大学学报,2001,25(6):449.
[32]王素美,徐红梅,吴延平.糖脂平颗粒对2型糖尿病合并高脂血症的临床研究[J].中国实验方剂学杂志,2002,8(4):60.
[33]邵敏,温凌洁,孙蓉.穴位敷贴对Ⅱ型糖尿病患者血脂水平的影响.上海针灸杂志2000,19(6):5.
[34]罗红艳,王晓红.傍针刺法为主治疗气阴两虚型消渴病 5 例临床观察.中国针灸,2000,(1):21.
[35]胡葵,李嘉.针灸治疗肥胖型NIDDM的临床研究.上海针灸杂志,2001;20(4):8.
[36]董卫.胃脘下俞穴埋线治疗糖尿病62例.上海针灸杂志,2002,(21):3.
[37]范冠杰,彭颖华.针药合用对非胰岛素依赖型糖尿病患者血脂影响临床研究.中国针灸,1998;18(3):139.
[38]吴宇宁,吕苑忠.加用活血降糖平脂方治疗2型糖尿病30例疗效观察[J].广西中医药,2003,26(3).
[39]陈凯,陈凤兰.中西医结合治疗高脂血症62例疗效观察[J].新中医,2006,38(1):58.
[40]Taskinen MR.Smith U.Lipid disorders in NIDDM:implications for treatment.Journal of Internal Medicine,1998,244:361-370.
[41]Barnett AH.Dyslipidaemia in diabetes-AGP guide.Practitioner,2002,246:120-123.
[42]Betteridge,DJ.Diabetic dyslipidaemia.Diabetes Obes Metab,2000 2:S31-36.
[43]郭啸华,刘志红,李恒.实验性2型糖尿病大鼠模型的建立肾脏病与透析肾移植杂志.2000;9(4):351.
[44]田浩明.游离脂肪酸与肥胖和糖尿病.实用糖尿病杂志,2000;2(2):8.
[45]钱学贤.致动脉硬化脂蛋白谱与代谢综合症.中华内科杂志,2000:39(2):80.
[46]Report of a WHO Study Group.Prevention of diabetes mellitus.World Health organ Tech Rep Ser,1994,844:1-100.
[47]全国糖尿病研究协作组调查研究组.全国14省市30万人口中糖尿病调查报告.中华内科杂志,1981,20:678.
[48]向红丁,王恒,孙琦,等.1989年山西析州、北京和辽宁地区糖尿病流行病学调查结果分析.中国糖尿病杂志,1993,1:16.
[49]向红丁,吴纬,刘灿群,等.1996年全国糖尿病流行病学特点基线调查报告.中国糖尿病杂志,1998,6(3):131-133.
[50]Udawat H,Goyal PK.Maheshwaria.Coronary risk and dyslipidemia in type 2diabetic patients.J.Assoc Physicians India,2001,49:970-973.
[51]潘长玉.中国糖尿病最新资料搜集研究.国外医学内分泌学分册,2002,22(3):135-137.
[52]何岚,程西峰,李海霞,等.2型糖尿病患者脂代谢状态及影响因素的探讨.陕西医学杂志,2004,33(345):265-266.
[53]Feher MD,Elkeles RS.LIPid modification and coronary heart disease in type 2diabetes:different from the general Population?Heart,1999,81(1):10-11.
[54]UKPDS Group.Tight blood pressure control and risk of maerovascuar and microvascular complications in type 2 diabetes.BMJ,1998,317(7160):703-713.
[55]McGarry JD.Dysregulation of fatty acid metabolism in the etiology of type 2diabetes.Diabetes,2001,50(Suppl 2):6.
[56]UK ProSPeetive diabetes study group.Plasma tipids and lipoproteins at diagnosis of NIDDM by ageand Sex:UKPDS 27.Diabetes care,1997;20:1683.
[57]Jeppesen J,Hein HO,Suadicani P,et al.Triglyceride concentration and ischemic heart disease,an eight-year follow-up in the copen-hagen male Study.Circulation,1998;97:1029.
[58]杨金奎,成金罗,刘煜等.家族性2型糖尿病遗传方式及血糖血脂代谢的研究.江苏临床医学杂志,2002,6(4):322-325.
[59]李光伟.2型糖尿病的胰岛素抵抗及其临床评估和处理.实用糖尿病杂志,1999,7(4):6.
[60]徐一甄,沈稚舟.胰岛素抵抗与血脂异常.国外医学内科学分册,1998,25(1):12.
[61]千正琦,沈更新,金惠玲.2型糖尿病脂肪肝与胰岛素抵抗、脂代谢的关系.浙江临床医学,2002,7(5):270-271.
[62]Taskinen MR et al.Eeffet of insulin therapy on metabolic fate of apolipoprotein containing Lipoproteins in NIDDM.Diabetes,1990,39:1017.
[63]JeppesenJ,Hein HO Suadicani P,et al Triglyceride concentration and Ischemic heart disease,an eight-year follow-up in the copen-hagen male study.Circulation,1998,97:1029.
[64]Kennedy GC.The role of depot fat in the hypothalamic control of food intake in the rat.Porc R Soe,1953,140:578-592.
[65]Hevrey GR.The effects of lesions in the hypothalmuas in Parabiotic rats.JPhys,1958,145:336-352.
[66]Zhang Y,proenca R,Maffei M,et al.Positional cloning of the mouse obesegene and its human homologue.[J]Natare,1994,372:425-432.
[67]Venesse VH,Reynisdorttir S,Eriksson P,et al.Leptin secretion from subcutaneous and visceral adipose tissue in women.[J]Diabetes,1998,47(6):913-917
[68]Caro JF Sinha MK,Kolaczynski JW et al.Leptin,the tale of an obesity gene.Dibaetes,1996,45:1455-1462.
[69]Houseknecht KL,Baile CA,Matteri RL,et al.The biology of leptin:a re-view.J Anim Sci,1998,76:1405-1420.
[70]Mueller WM,Gregoier FM,Stanhope KL,et al.Evidence that glucose metabolism regulates Leptin secretin form cultured rat adipocytes.Endocrinology,1998,139:551-555.
[71]Halaas JLGajiwala KS,Maffei M,et al.Weight-reducing effects of the plasma protein encoded by the obese gene.Seienee,1995,269:543-546.
[72]Pelleymounter MA,Cullen MJ,Baker MB,et al.Eeffcts of the obese gene Product on body weight regulation in ob/ob mice.Seienee,1995,269:540-543.
[73]Grilardi N,Skoda RC.The leptin receptor activates Janus kinase 2 and signals for proliferation in a factor-dependent cell1 line.[J]Mol Endocrinol,1997,11:393-399.
[74]Trayhurn P,Hoggard N,Mercer JG,et al.Leptin:fundmental aspects.[J]Int J Obese Relat Matab Disord,1999,23 Suppl 1:22-28.
[75]Caro JF,Kolaczynski JW,Nyce MR,et al.Decreased cerebro spinal-fluid/serum leptin ratio in obesity:a possible machism for leptin resistance.[J]Lancet,1996,348:159-161.
[76]田成功,邵加庆,于镔.瘦素:胰岛素抵抗的独立危险因素.[J].中华内分泌代谢杂志,2002,18(6):184-187.
[77]De Courten M,Zimmet P,Hodge A,et al.Hyperleptinemia:the missing link in the metabolism syndrome.[J]Diabet Med 1997,14(3):200-208
[78]Mohamed-Ali V,Pinkey JH,Panahloo A,et al.Relationship between plasma leptin and insulin concentration,but not insulin resistance,in non-insulin-dependence (type 2)diabetes mellitus.[J]Diabet Med,1997,14(5):376-380
[79]Maffei M,Stoffel M,Barone B,et al.Absence of mutations in the human OB gene in obese/diabetic subjects.Diabetes,1996,45(5):679-82.
[80]Kakuma T,Lee Y,Higa M,et al.Leptin,troglitazone,and the expression of sterol regulatory element-binding proteins in liver and pancreatic islets.Proc Natl Acad Sci USA,2000,97:8536-8541.
[81]Loffeda S,Yang SQ,Lin HZ,et al.Leptin regulates proinflammatory immune responses.FASEB J,1998,12:57-65.
[82]Bai Y,Zhang S,Kin KS,et al.Obese gene expression alters the ability of 30A5preadipocytes to lipogenic hormones.[J]J Biol Chem,1996,271(24):13939-13942.
[83]Ogawa Y,Masuzaki H,Hosada K,.et al.Increased glucose metabolism and insulin sensitivity in Transgenic Skimy Mice over expressing leptin.[J]Diabetes,1999,48:1822-1829.
[84]董小燕,葛青玮,田国力,等.儿童血清瘦素水平及其糖脂代谢关系的初步探讨.[J]中华预防医学杂志,2002,36(2):137-138.
[85]Couillard C,Lamarche B,Mauriege P,et al.Leptinemia is not a risk factor for ischemic heat disease in men.Prospective results from the Quebuc Cardiovascular study.[J]Diabetes Care,1998,21(5):782-786.
[86]Leyva F,Lodsland IF,Ghatei M,et al.Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk.[J]Ariterioscler Thromb Vasc Biol,1998,18(6):928-933.
[87]中药大词典.上海科学技术出版社,1993第五版下册,1596-1599.
[88]蔡缨,沈忠松.茯苓对2型糖尿病患者的降糖作用.解放军医学杂志,2001,26(5):371-372.
[89]杨新波,黄正明,曹文斌,等.泽泻提取物对链脲佐菌素高血糖小鼠的治疗和保护作用.解放军药学学报,2002,18(6):336-338,350.
[90]王树立,李永德,赵勤.山楂、黄芪及刺五加对豚鼠胆固醇代谢的应影响.中国中西医结合杂志,1987;7(8):483.
[91]沈志卫,于普林,孙美珍,等.血脂康治疗原发性高脂血症的前瞻性研究.中华医学杂志,1996,76(2):156-157
[92]王显俊,苏梅者,陆宗良,等.血脂康胶囊治疗高脂血症临床观察.中国实验方剂杂志,1995,1(11):1-5
[93]刘忠铭,赵力.血脂康治疗高脂血症的临床观察.中华医学杂志,1996,9:12.
[94]邵淑丽.柴胡、姜黄对小白鼠实验性高脂血症的预防作用.中医药学报,2002,30(4):59.
[95]赵春亭,赵子文.临床血液流变学[M].北京:人民卫生出版社,1997,167-75.
[96]李永民.中药克糖宁对实验性糖尿病血流变的影响[J].张家口医学院学报,2003,20(5):16-18.
[97] P.J.Havel.Control of energy homeostasis and insulin action by adipocyte homrones:Leptin ,acylation stimulating protein and adiponectin[J]Curr.Opin. Lipidol, 2002;(13):51-59.
[98] T.J.Kieffer, J.F.Habener.The adipoinsular axis.effects of leptin on pancreatic beta-cells.[J]Am.J.Physiol.2000:(278):E1-E14.
[99] Kamohara S,Burcelin R,Halaas JL,Friedman JM,Charron MJ:Acute stimulation of glucose metabolism in mice by Leptin treatment.[J]Nature, 1997:389:374-377.
[100] Cusin I,Zakrzewska KE,Boss O.Chronic central Leptin infusionenhances insulin-stimulated glucose metabolism and favors the expression of uncoupling porteins.[J]Diabetes,1998:47:1014-1019.
[101] Muller G,Prins J B,Niesler C V,et al. LePtin impairs metabolic action of insulin in isolated rat adipocytes.[J].Diabetes,1997,46:1939-1944.
[2]Barzilay JI,AbrahamL,Heckbert SR,et al.The relation of markers of Inflammation to the development of glueose disorders in the elderly:the Cardiovascular health study[J].Diabetes,2001,50:2384.
[3]Pradhan AD,Manson JE,Rifai N,etal.C-reaetive protein,inter leukine,and risk of developing type 2 diabetes mellitus[J].JAMA,2001,286:327.
[4]杨金奎,成金罗等 家族性2型糖尿病遗传方式及血糖血脂代谢的研究.[J].江苏临床医学杂志,2002,6(4):322-324.
[5]卢薇,汪晓云,杨正平等2型糖尿病患者餐后血糖、血脂与凝血及血小板活性关系[J].临床内科杂志,2002,19(6):472-473.
[6]张英新.益气健脾法与糖尿病.山东中医学院杂志,1995;(6):391.
[7]邢玖.从“脾”论治糖尿病-附30例疗效分析.中医药研究,1997;(5):18.
[8]郑庆瑞.健脾补肾活血化癖治疗性糖尿病.新中医,1996:28(4):58.
[9]杨坚毅.老年高脂血症的中医分型治疗.新中医,1996;28(8):6.
[10]靳瑞主编.针灸医籍选.人民卫生出版社,1990;113.
[11]《袖珍中医四部经典》.天津科学技术出版社,1992;90-91.
[12]张兆云.中医药防止高脂血症信息分析.中国中医药信息杂志,1994;(6):33.
[13]李中梓.《医宗必读》.三余堂详较本,卷9:16.
[14]张景岳.《景岳全书》.上海科学技术出版社,1980年:531.
[15]丁汀辨病与辨证相结合治疗高脂血症[J].天津药学,200315(1):34.
[16]倪青.脾胃肾虚生痰湿祛痰利湿重健脾.辽宁中医杂志,2001,28(4):195-196.
[17]丁宇炜,徐瑛,沈丕安.中医分型治疗高脂血症45例观察[J].内蒙古中医药,2003(4):1.
[18]卢秀鸾,曲竹秋,贾锡莲.降糖克脂胶囊治疗老年性糖尿病合并高血脂症68例观察.中草药,2000,31(5):368.
[19]崔衍富.血塞通结合辨证治疗高脂血症100例[J]辽宁中医杂志,1997,24(9):403.
[20]何锦花.高脂血症辨证施治[J]广西中医药,1995,18(1):23.
[21]高雷,林海平,王超.补肾通脉丸治疗糖尿病并发高脂血症368例[J].辽宁中医杂志,2003,30(8):616.
[22]王旭.益肾活血化浊法治疗老年糖尿病合并高脂血症的临床研究[A].第四届全国糖尿病(消渴病)学术研讨会论文集[C].济南:山东科学技术出版社,1997,71-72.
[23]汪何.吕雄.刘乡等.中西医结合治疗 2 型糖尿病合并高脂血症[J].广东医学,2002,23(2):201.
[24]沈志卫,于普林.血脂康治疗原发性高血脂的前瞻性研究.中华医学杂志,1996,76(2):156.
[25]肖超烈,姚志强,贺淑梅.血脂康与脂必妥对高胆固醇血症的调脂作用比较[J].广东医学,2000,21(51):349.
[26]孙炜.祛瘀化痰通络论治糖尿病高脂血症56例[J].中国医药学报,2003,18(8):508
[27]龚振岭,靳国春,康胜群.胰体康胶囊治疗2型糖尿病125例临床研究[J].河北中医,2002,24(2):83-86.
[28]周晓,张炜宁,曾庆明,等.清化消瘀方治疗2型糖尿病合并高脂血症36例总结[J]湖南中医杂志,2003,19(4):13.
[29]王红,申凤菊三参二根汤治疗2型糖尿病并高脂血症[J].山东医药工业,2003,22(4):58
[30]吴深涛,黄怀鹏,邬金玲等.肾消颗粒对早期糖尿病影响的研究.天津中医药,2004,21(6):473.
[31]郭宝荣,冯建华,杨文军.降糖活血调脂汤治疗糖尿病合并高脂血症52例[J].山东中医药大学学报,2001,25(6):449.
[32]王素美,徐红梅,吴延平.糖脂平颗粒对2型糖尿病合并高脂血症的临床研究[J].中国实验方剂学杂志,2002,8(4):60.
[33]邵敏,温凌洁,孙蓉.穴位敷贴对Ⅱ型糖尿病患者血脂水平的影响.上海针灸杂志2000,19(6):5.
[34]罗红艳,王晓红.傍针刺法为主治疗气阴两虚型消渴病 5 例临床观察.中国针灸,2000,(1):21.
[35]胡葵,李嘉.针灸治疗肥胖型NIDDM的临床研究.上海针灸杂志,2001;20(4):8.
[36]董卫.胃脘下俞穴埋线治疗糖尿病62例.上海针灸杂志,2002,(21):3.
[37]范冠杰,彭颖华.针药合用对非胰岛素依赖型糖尿病患者血脂影响临床研究.中国针灸,1998;18(3):139.
[38]吴宇宁,吕苑忠.加用活血降糖平脂方治疗2型糖尿病30例疗效观察[J].广西中医药,2003,26(3).
[39]陈凯,陈凤兰.中西医结合治疗高脂血症62例疗效观察[J].新中医,2006,38(1):58.
[40]Taskinen MR.Smith U.Lipid disorders in NIDDM:implications for treatment.Journal of Internal Medicine,1998,244:361-370.
[41]Barnett AH.Dyslipidaemia in diabetes-AGP guide.Practitioner,2002,246:120-123.
[42]Betteridge,DJ.Diabetic dyslipidaemia.Diabetes Obes Metab,2000 2:S31-36.
[43]郭啸华,刘志红,李恒.实验性2型糖尿病大鼠模型的建立肾脏病与透析肾移植杂志.2000;9(4):351.
[44]田浩明.游离脂肪酸与肥胖和糖尿病.实用糖尿病杂志,2000;2(2):8.
[45]钱学贤.致动脉硬化脂蛋白谱与代谢综合症.中华内科杂志,2000:39(2):80.
[46]Report of a WHO Study Group.Prevention of diabetes mellitus.World Health organ Tech Rep Ser,1994,844:1-100.
[47]全国糖尿病研究协作组调查研究组.全国14省市30万人口中糖尿病调查报告.中华内科杂志,1981,20:678.
[48]向红丁,王恒,孙琦,等.1989年山西析州、北京和辽宁地区糖尿病流行病学调查结果分析.中国糖尿病杂志,1993,1:16.
[49]向红丁,吴纬,刘灿群,等.1996年全国糖尿病流行病学特点基线调查报告.中国糖尿病杂志,1998,6(3):131-133.
[50]Udawat H,Goyal PK.Maheshwaria.Coronary risk and dyslipidemia in type 2diabetic patients.J.Assoc Physicians India,2001,49:970-973.
[51]潘长玉.中国糖尿病最新资料搜集研究.国外医学内分泌学分册,2002,22(3):135-137.
[52]何岚,程西峰,李海霞,等.2型糖尿病患者脂代谢状态及影响因素的探讨.陕西医学杂志,2004,33(345):265-266.
[53]Feher MD,Elkeles RS.LIPid modification and coronary heart disease in type 2diabetes:different from the general Population?Heart,1999,81(1):10-11.
[54]UKPDS Group.Tight blood pressure control and risk of maerovascuar and microvascular complications in type 2 diabetes.BMJ,1998,317(7160):703-713.
[55]McGarry JD.Dysregulation of fatty acid metabolism in the etiology of type 2diabetes.Diabetes,2001,50(Suppl 2):6.
[56]UK ProSPeetive diabetes study group.Plasma tipids and lipoproteins at diagnosis of NIDDM by ageand Sex:UKPDS 27.Diabetes care,1997;20:1683.
[57]Jeppesen J,Hein HO,Suadicani P,et al.Triglyceride concentration and ischemic heart disease,an eight-year follow-up in the copen-hagen male Study.Circulation,1998;97:1029.
[58]杨金奎,成金罗,刘煜等.家族性2型糖尿病遗传方式及血糖血脂代谢的研究.江苏临床医学杂志,2002,6(4):322-325.
[59]李光伟.2型糖尿病的胰岛素抵抗及其临床评估和处理.实用糖尿病杂志,1999,7(4):6.
[60]徐一甄,沈稚舟.胰岛素抵抗与血脂异常.国外医学内科学分册,1998,25(1):12.
[61]千正琦,沈更新,金惠玲.2型糖尿病脂肪肝与胰岛素抵抗、脂代谢的关系.浙江临床医学,2002,7(5):270-271.
[62]Taskinen MR et al.Eeffet of insulin therapy on metabolic fate of apolipoprotein containing Lipoproteins in NIDDM.Diabetes,1990,39:1017.
[63]JeppesenJ,Hein HO Suadicani P,et al Triglyceride concentration and Ischemic heart disease,an eight-year follow-up in the copen-hagen male study.Circulation,1998,97:1029.
[64]Kennedy GC.The role of depot fat in the hypothalamic control of food intake in the rat.Porc R Soe,1953,140:578-592.
[65]Hevrey GR.The effects of lesions in the hypothalmuas in Parabiotic rats.JPhys,1958,145:336-352.
[66]Zhang Y,proenca R,Maffei M,et al.Positional cloning of the mouse obesegene and its human homologue.[J]Natare,1994,372:425-432.
[67]Venesse VH,Reynisdorttir S,Eriksson P,et al.Leptin secretion from subcutaneous and visceral adipose tissue in women.[J]Diabetes,1998,47(6):913-917
[68]Caro JF Sinha MK,Kolaczynski JW et al.Leptin,the tale of an obesity gene.Dibaetes,1996,45:1455-1462.
[69]Houseknecht KL,Baile CA,Matteri RL,et al.The biology of leptin:a re-view.J Anim Sci,1998,76:1405-1420.
[70]Mueller WM,Gregoier FM,Stanhope KL,et al.Evidence that glucose metabolism regulates Leptin secretin form cultured rat adipocytes.Endocrinology,1998,139:551-555.
[71]Halaas JLGajiwala KS,Maffei M,et al.Weight-reducing effects of the plasma protein encoded by the obese gene.Seienee,1995,269:543-546.
[72]Pelleymounter MA,Cullen MJ,Baker MB,et al.Eeffcts of the obese gene Product on body weight regulation in ob/ob mice.Seienee,1995,269:540-543.
[73]Grilardi N,Skoda RC.The leptin receptor activates Janus kinase 2 and signals for proliferation in a factor-dependent cell1 line.[J]Mol Endocrinol,1997,11:393-399.
[74]Trayhurn P,Hoggard N,Mercer JG,et al.Leptin:fundmental aspects.[J]Int J Obese Relat Matab Disord,1999,23 Suppl 1:22-28.
[75]Caro JF,Kolaczynski JW,Nyce MR,et al.Decreased cerebro spinal-fluid/serum leptin ratio in obesity:a possible machism for leptin resistance.[J]Lancet,1996,348:159-161.
[76]田成功,邵加庆,于镔.瘦素:胰岛素抵抗的独立危险因素.[J].中华内分泌代谢杂志,2002,18(6):184-187.
[77]De Courten M,Zimmet P,Hodge A,et al.Hyperleptinemia:the missing link in the metabolism syndrome.[J]Diabet Med 1997,14(3):200-208
[78]Mohamed-Ali V,Pinkey JH,Panahloo A,et al.Relationship between plasma leptin and insulin concentration,but not insulin resistance,in non-insulin-dependence (type 2)diabetes mellitus.[J]Diabet Med,1997,14(5):376-380
[79]Maffei M,Stoffel M,Barone B,et al.Absence of mutations in the human OB gene in obese/diabetic subjects.Diabetes,1996,45(5):679-82.
[80]Kakuma T,Lee Y,Higa M,et al.Leptin,troglitazone,and the expression of sterol regulatory element-binding proteins in liver and pancreatic islets.Proc Natl Acad Sci USA,2000,97:8536-8541.
[81]Loffeda S,Yang SQ,Lin HZ,et al.Leptin regulates proinflammatory immune responses.FASEB J,1998,12:57-65.
[82]Bai Y,Zhang S,Kin KS,et al.Obese gene expression alters the ability of 30A5preadipocytes to lipogenic hormones.[J]J Biol Chem,1996,271(24):13939-13942.
[83]Ogawa Y,Masuzaki H,Hosada K,.et al.Increased glucose metabolism and insulin sensitivity in Transgenic Skimy Mice over expressing leptin.[J]Diabetes,1999,48:1822-1829.
[84]董小燕,葛青玮,田国力,等.儿童血清瘦素水平及其糖脂代谢关系的初步探讨.[J]中华预防医学杂志,2002,36(2):137-138.
[85]Couillard C,Lamarche B,Mauriege P,et al.Leptinemia is not a risk factor for ischemic heat disease in men.Prospective results from the Quebuc Cardiovascular study.[J]Diabetes Care,1998,21(5):782-786.
[86]Leyva F,Lodsland IF,Ghatei M,et al.Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk.[J]Ariterioscler Thromb Vasc Biol,1998,18(6):928-933.
[87]中药大词典.上海科学技术出版社,1993第五版下册,1596-1599.
[88]蔡缨,沈忠松.茯苓对2型糖尿病患者的降糖作用.解放军医学杂志,2001,26(5):371-372.
[89]杨新波,黄正明,曹文斌,等.泽泻提取物对链脲佐菌素高血糖小鼠的治疗和保护作用.解放军药学学报,2002,18(6):336-338,350.
[90]王树立,李永德,赵勤.山楂、黄芪及刺五加对豚鼠胆固醇代谢的应影响.中国中西医结合杂志,1987;7(8):483.
[91]沈志卫,于普林,孙美珍,等.血脂康治疗原发性高脂血症的前瞻性研究.中华医学杂志,1996,76(2):156-157
[92]王显俊,苏梅者,陆宗良,等.血脂康胶囊治疗高脂血症临床观察.中国实验方剂杂志,1995,1(11):1-5
[93]刘忠铭,赵力.血脂康治疗高脂血症的临床观察.中华医学杂志,1996,9:12.
[94]邵淑丽.柴胡、姜黄对小白鼠实验性高脂血症的预防作用.中医药学报,2002,30(4):59.
[95]赵春亭,赵子文.临床血液流变学[M].北京:人民卫生出版社,1997,167-75.
[96]李永民.中药克糖宁对实验性糖尿病血流变的影响[J].张家口医学院学报,2003,20(5):16-18.
[97] P.J.Havel.Control of energy homeostasis and insulin action by adipocyte homrones:Leptin ,acylation stimulating protein and adiponectin[J]Curr.Opin. Lipidol, 2002;(13):51-59.
[98] T.J.Kieffer, J.F.Habener.The adipoinsular axis.effects of leptin on pancreatic beta-cells.[J]Am.J.Physiol.2000:(278):E1-E14.
[99] Kamohara S,Burcelin R,Halaas JL,Friedman JM,Charron MJ:Acute stimulation of glucose metabolism in mice by Leptin treatment.[J]Nature, 1997:389:374-377.
[100] Cusin I,Zakrzewska KE,Boss O.Chronic central Leptin infusionenhances insulin-stimulated glucose metabolism and favors the expression of uncoupling porteins.[J]Diabetes,1998:47:1014-1019.
[101] Muller G,Prins J B,Niesler C V,et al. LePtin impairs metabolic action of insulin in isolated rat adipocytes.[J].Diabetes,1997,46:1939-1944.